Jasper Therapeutics (JSPR) said Wednesday that preliminary data from an ongoing phase 1b/2a study of subcutaneously administered briquilimab as a treatment for chronic spontaneous urticaria showed "substantial reductions" in disease activity.
The company said the 49-patient study showed clinical responses as early as one week after the first dose as well as "durable" clinical responses across multiple doses.
Chronic spontaneous urticaria is a condition which causes hives to appear.
Jasper Therapeutics' shares were down 44% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。